Drug profile

The FDA adverse-event record for Purevax Feline Rabies 3 - 1901.R4

20 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Purevax Feline Rabies 3 - 1901.R4. See the species affected, top reactions, and outcomes below.

20
adverse-event reports
5.0%
death-coded share
Cat
most-reported species
6
Lethargy (see also Central nervous system depression in Neurological) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
20
Total Reports
1
Deaths Reported
5.0%
Death Rate

Active Ingredients

Purevax Feline Rabies 3 - 1901.R4

Administration Routes

SubcutaneousUnknown

Species Affected

Cat 19
Dog 1

Most Affected Breeds

Domestic Shorthair 13
Domestic Mediumhair 2
Shiba Inu 1
Scottish Fold Longhair 1
American Shorthair 1
American Curl Shorthair 1
Turkish Angora 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 6
Lethargy (see also Central nervous system depression in 'Neurological') 5
Fever 5
Vomiting 5
Behavioural disorder NOS 3
Warm feeling to the touch 3
Tachypnoea 2
Febrile 2
Aggression 2
Inappetence 2
Anorexia 2
Pain NOS 2

Outcome Breakdown

Recovered/Normal
10 (50.0%)
Outcome Unknown
6 (30.0%)
Ongoing
3 (15.0%)
Died
1 (5.0%)

Purevax Feline Rabies 3 - 1901.R4 Adverse Event Insights

20 reports name Purevax Feline Rabies 3 - 1901.R4; 1 recorded a death outcome (5.0% of reported events, not a population-level mortality rate). Active ingredient: Purevax Feline Rabies 3 - 1901.R4. Administration routes: Subcutaneous, Unknown.

By species: Cat (19 reports), Dog (1 reports). By breed: Domestic Shorthair (13), Domestic Mediumhair (2), Shiba Inu (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in Neurological) (6), Lethargy (see also Central nervous system depression in 'Neurological') (5), Fever (5), Vomiting (5). Outcome, 20 coded reports: Recovered/Normal leads at 50.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.